<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01198249</url>
  </required_header>
  <id_info>
    <org_study_id>4-2010-0295</org_study_id>
    <nct_id>NCT01198249</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Drug Interactions Between Single and Concomitant Administrations of Amlodipine, Losartan, and Hydrochlorothiazide in Subjects With (Pre)Hypertension</brief_title>
  <official_title>A Randomized, Open Label, Multiple Dose, Crossover Study to Investigate Pharmacokinetic Drug Interactions Between Single and Concomitant Administrations of Amlodipine, Losartan, and Hydrochlorothiazide(HCTZ) in Subjects With (Pre)Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aimed to evaluate the pharmacokinetics and the drug-drug interaction among
      anti-hypertension drugs-amlodipine, losartan, and hydrochlorothiazide. This pilot study
      provides useful information to develop a new fixed dose combination drug.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>amlodipine monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>losartan monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HCTZ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>mlodipine and Losartan and HCTZ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>multiple dose, crossover study between single and concomitant administrations of amlodipine, losartan, and hydrochlorothiazide</intervention_name>
    <description>amlodipine 10 mg for 9 days , losartan 100 mg for 9 days, hydrochlorothiazide (HCTZ) 25 mg for 9 days and combination of amlodipine 10 mg, losartan 100 mg and hydrochlorothiazide (HCTZ) 25 mg for 9 days, 4 way crossover study</description>
    <arm_group_label>amlodipine monotherapy</arm_group_label>
    <arm_group_label>losartan monotherapy</arm_group_label>
    <arm_group_label>HCTZ</arm_group_label>
    <arm_group_label>mlodipine and Losartan and HCTZ</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subjects 20-50 years of age

          -  Above 55Kg and within ±20% ideal body weight

          -  Subjects who are in average of 130mmHg ≤ systolic blood pressure (SBP) &lt; 160mmHg,
             80mmHg ≤ diastolic blood pressure (DBP) &lt; 100mmHg

          -  Female subject who confirmed non-pregnant status and agree to comply with proper
             contraception.

          -  Subjects who wrote informed consent

        Exclusion Criteria:

          -  Subjects who are suspected to have acute disease

          -  Subjects who have past history that may affect drug absorption, distribution,
             metabolism and elimination

          -  Subjects who have gastrointestinal history

          -  Subjects whose heartrate is less than 60

          -  Subject who suspected to orthostatic hypotension

          -  Subjects who have clinically significant allergy disease

          -  Subject is currently participating or has participating in a study with an
             investigational compound or device within 30 days of signing informed consent

          -  Administration of prescription drug within 14 days or over the counter (OTC) drug
             within 7 days

          -  Subjects who have past history of drug abuse and positive in drug screening test

          -  Subjects who donate whole blood within 60 days and platelet within 30days.

          -  Subjects taking St John's wort or CYP inhibitor and inducer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae-Yong Chung, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2010</study_first_submitted>
  <study_first_submitted_qc>September 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2010</study_first_posted>
  <last_update_submitted>March 25, 2011</last_update_submitted>
  <last_update_submitted_qc>March 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2011</last_update_posted>
  <responsible_party>
    <name_title>Kyung-Mi Park / Director</name_title>
    <organization>Hanmi Pharmaceutial Co., Ltd.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

